Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
134.3 USD | -0.86% | +4.53% | -2.63% |
25/04 | Labcorp beats quarterly estimates on strong testing demand | RE |
24/04 | Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155 | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.63% | 14.92B | A- | ||
-14.92% | 84.68B | B- | ||
+13.30% | 81.12B | C+ | ||
+10.92% | 29.4B | C+ | ||
-12.71% | 16.73B | B | ||
-3.06% | 16.36B | A- | ||
-31.75% | 11.77B | - | - | |
-1.42% | 11.72B | A- | ||
+27.44% | 11.71B | B- | ||
-3.97% | 11.66B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DGX Stock
- Ratings Quest Diagnostics Incorporated